We are excited to announce the settlement of this class action lawsuit. The case involved alleged pay-for-delay antitrust violations by various defendants. Plaintiffs alleged that Defendants unlawfully delayed the availability of allegedly less-expensive generic versions of Zetia and that Defendants’ alleged conduct caused third-party payors to pay too much for branded and generic Zetia in select states. The Court has preliminarily approved the proposed settlement, which will provide for the payment of $70,000,000.00 to resolve the end-payor claims against them. The full text of the proposed settlement agreement is available here.